Cover Image
市場調查報告書

神經退化性疾病的全球市場 (2015∼2019年)

Global Neurodegenerative Diseases Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 329645
出版日期 內容資訊 英文 168 Pages
訂單完成後即時交付
價格
Back to Top
神經退化性疾病的全球市場 (2015∼2019年) Global Neurodegenerative Diseases Market 2015-2019
出版日期: 2015年05月06日 內容資訊: 英文 168 Pages
簡介

所謂神經退化性疾病,是由於腦內部的神經原相關的症狀,帶給人體的平衡和動作,發育,呼吸、心率功能不良影響。關於原因還不明白,治療方法也沒確立。神經細胞階段性變質,對人體有很大消耗,最終死亡。還有引起運動失調和癡呆症等,也大幅影響患者的心理健康。神經退化性疾病的主要類型,有老年癡呆症和帕金森氏症、亨丁頓舞蹈症、多發性硬化症、ALS (肌肉萎縮性側索硬化症)、癲癇等。其中老年癡呆症和帕金森氏症發病數量比較多,不過,亨丁頓舞蹈症和ALS歸類於難治之症。全球神經退化性疾病市場2014∼2019年,預計以4.77%的年複合成長率(CAGR) 成長。

本報告提供全球的神經退化性疾病的相關市場相關分析、疾病概要和主要的治療藥、市場規模趨勢 (今後5年的預測值)、主要的各疾病、各分子類型、各給藥途徑、各地區的詳細趨勢、推動、阻礙市場要素與其影響力、主要企業簡介、今後的市場機會等調查、考察。

第1章 摘要整理

第2章 簡稱集

第3章 分析範圍

  • 市場概要
  • 主要的產品

第4章 產品簡介 (共18個品項)

第5章 市場分析技術

  • 市場分析的流程
  • 分析方法

第6章 簡介

第7章 市場環境

  • 市場概況
  • 市場規模與其預測
  • 波特的五力分析

第8章 神經退化性疾病的全球市場:疾病的各種類的明細

第9章 多發性硬化症的全球市場

  • 多發性硬化症概要
    • 疾病概要
    • 症狀
    • 病因
    • 流行病學
    • 經濟負擔
  • 市場概要
  • 市場規模與其預測
  • 美國市場:市場規模與預測

第10章 老年癡呆症的全球市場

第11章 癲癇的全球市場

第12章 帕金森氏症的全球市場

第13章 亨丁頓舞蹈症的全球市場

第14章 肌肉萎縮性側索硬化症(ALS) 的全球市場

第15章 神經退化性疾病的全球市場的明細:各分子類型

  • 生技藥品
  • 小分子

第16章 神經退化性疾病的全球市場的明細:各給藥途徑

  • 口服
  • 非口服
  • 局部

第17章 地區區分

第18章 購買標準

第19章 促進市場成長的要素

第20章 推動因素與其影響力

第21章 市場課題

第22章 推動因素、課題的影響力

第23章 市場趨勢

第24章 市場趨勢與其影響

第25章 供應商環境

  • 競爭方案
    • 近幾年的主要趨勢
    • 企業合併、收購 (M&A)
  • 市場佔有率分析
    • 主要醫藥品的競爭評估
  • 其他著名的/具未來性的供應商

第26章 主要供應商分析

  • Biogen Idec
    • 主要資料
    • 產業概要
    • 各部門的市場收益額
    • 各地區的市場收益額
    • 產業策略
    • 最近的發展趨勢
    • SWOT分析
  • Merck Serono
  • Novartis
  • Pfizer
  • Teva Pharmaceutical
  • UCB

第27章 相關報告

圖表一覽

目錄
Product Code: IRTNTR5793

About neurodegenerative diseases

According to the EU JPND, neurodegenerative diseases refer to conditions that involve the neurons in the brain. These conditions can affect balance, movement, speech, and respiratory and cardiac functions. They can be inherited or be of unknown etiology. Neurodegenerative diseases are incurable and are severely debilitating. They result in progressive degeneration of nerve cells, causing them to die eventually. These diseases cause ataxia and dementia in people, which can have a serious impact on the mental health of patients. Some examples of neurodegenerative diseases are Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, amyotrophic lateral sclerosis, and epilepsy. Huntington's disease and amyotrophic lateral sclerosis are rare diseases, unlike Alzheimer's disease and Parkinson's disease which have a high degree of prevalence.

Technavio's analysts forecast the global neurodegenerative diseases market to grow at a CAGR of 4.77 percent over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the global neurodegenerative diseases market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of neurodegenerative diseases. The market includes data from the sales of various drugs used in the treatment of:

  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Epilepsy
  • Huntington's Disease
  • Amyotrophic Lateral Sclerosis

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the global neurodegenerative diseases market. The vendor landscape section includes a market share analysis of the major vendors along with the performances of their product portfolios. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market. In addition, late-stage pipeline molecules developed for the treatment of neurodegenerative diseases are discussed.

Technavio's report, Global Neurodegenerative Diseases Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the EMEA, and the APAC; it also covers the global neurodegenerative diseases market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • Biogen Idec
  • Merck Serono
  • Novartis
  • Pfizer
  • Teva Pharmaceutical Industries
  • UCB

Other prominent vendors

  • AB Science
  • Abbvie
  • Acorda Therapeutics
  • Actavis
  • Active Biotech
  • Adamas Pharmaceuticals
  • Akorn
  • Archer Pharmaceuticals
  • Astellas
  • Auspex Pharmaceuticals
  • Bayer
  • Boehringer Ingelheim
  • Covis
  • Desitin Arzneimittel
  • Eisai
  • Eli Lilly
  • Endo International
  • F. Hoffmann-La Roche
  • FORUM Pharmaceuticals
  • GlaxoSmithKline
  • Glenmark
  • H. Lundbeck
  • Ipsen
  • Janssen Pharmaceuticals
  • Kyowa Hakko Kirin
  • Mitsubishi Tanabe
  • MorphoSys
  • Newron Pharmaceuticals
  • Omeros
  • Opexa
  • Orion
  • Otsuka Pharmaceutical
  • Oxford BioMedica
  • Palobiofarma
  • Prana Biotechnology
  • Raptor Pharmaceutical
  • Sanofi
  • Siena Biotech
  • SOM Biotech
  • STADA
  • Takeda Pharmaceutical
  • TauRx Pharmaceuticals
  • US WorldMeds
  • Valeant
  • Zinfandel Pharmaceuticals

Market driver

  • High unmet medical needs
  • For a full, detailed list, view our report

Market challenge

  • Generic erosion
  • For a full, detailed list, view our report

Market trend

  • Reformulation of marketed drugs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Product Profiles

    • 04.1.1. Avonex/Rebif
    • 04.1.2. Plegridy
    • 04.1.3. Tecfidera
    • 04.1.4. Tysabri
    • 04.1.5. Comtan
    • 04.1.6. Stalevo
    • 04.1.7. Exelon/Exelon Patch
    • 04.1.8. Extavia
    • 04.1.9. Gilenya
    • 04.1.10. Cerebyx
    • 04.1.11. Dilantin-125
    • 04.1.12. Lyrica
    • 04.1.13. Neurontin
    • 04.1.14. Zarontin
    • 04.1.15. Azilect
    • 04.1.16. Copaxone
    • 04.1.17. Keppra/Keppra XR
    • 04.1.18. Neupro
    • 04.1.19. Vimpat

05. Market Research Methodology

  • 05.1. Market Research Process
  • 05.2. Research Methodology

06. Introduction

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Five Forces Analysis

08. Segmentation of Global Neurodegenerative Diseases Market by Type of Disease

09. Global Multiple Sclerosis Market

  • 09.1. Multiple Sclerosis: Overview
    • 09.1.1. About the Disease
    • 09.1.2. Symptoms
    • 09.1.3. Etiology
    • 09.1.4. Epidemiology
    • 09.1.5. Economic Burden
  • 09.2. Market Overview
  • 09.3. Market Size and Forecast
  • 09.4. Multiple Sclerosis Market in US
    • 09.4.1. Market Size and Forecast

10. Global Alzheimer's Disease Market

  • 10.1. Alzheimer's Disease: Overview
    • 10.1.1. About the Disease
    • 10.1.2. Dementia
    • 10.1.3. Epidemiology and Forecast
    • 10.1.4. Types of Dementia
    • 10.1.5. Global Burden
    • 10.1.6. Etiology
    • 10.1.7. Cost of Care
    • 10.1.8. Alzheimer's Disease and Caregiving
  • 10.2. Market Overview
  • 10.3. Market Size and Forecast

11. Global Epilepsy Market

  • 11.1. Epilepsy: Overview
    • 11.1.1. About the Disease
    • 11.1.2. Etiology
    • 11.1.3. Types of Epilepsy
    • 11.1.4. Symptoms
    • 11.1.5. Epidemiology
    • 11.1.6. Economic Burden
  • 11.2. Market Overview
  • 11.3. Market Size and Forecast
  • 11.4. Epilepsy Market in US
    • 11.4.1. Market Size and Forecast
  • 11.5. Epilepsy Market in Europe
    • 11.5.1. Market Size and Forecast
  • 11.6. Epilepsy Market in Japan
    • 11.6.1. Market Size and Forecast

12. Global Parkinson's Disease Market

  • 12.1. Parkinson's Disease: Overview
    • 12.1.1. About the Disease
    • 12.1.2. Symptoms
    • 12.1.3. Etiology
    • 12.1.4. Epidemiology
    • 12.1.5. Economic Burden
  • 12.2. Market Overview
  • 12.3. Market Size and Forecast

13. Global Huntington's Disease Market

  • 13.1. Huntington's Disease: Overview
    • 13.1.1. About the Disease
    • 13.1.2. Symptoms
    • 13.1.3. Etiology
    • 13.1.4. Prevalence of Huntington's Disease
    • 13.1.5. Pipeline Portfolio
    • 13.1.6. Economic Burden
  • 13.2. Market Overview
  • 13.3. Market Size and Forecast

14. Global Amyotrophic Lateral Sclerosis Market

  • 14.1. Amyotrophic Lateral Sclerosis: Overview
    • 14.1.1. About the Disease
    • 14.1.2. Types of Amyotrophic Lateral Sclerosis
    • 14.1.3. Etiology and Pathophysiology
    • 14.1.4. Symptoms
    • 14.1.5. Epidemiology
    • 14.1.6. Diagnosis
    • 14.1.7. Pipeline Portfolio
  • 14.2. Market Overview
  • 14.3. Market Size and Forecast

15. Segmentation of Global Neurodegenerative Diseases Market by Type of Molecule

  • 15.1. Biologics
  • 15.2. Small Molecules

16. Segmentation of Global Neurodegenerative Diseases Market by Route of Administration

  • 16.1. Oral
  • 16.2. Parenteral
  • 16.3. Topical

17. Geographical Segmentation

18. Buying Criteria

19. Market Growth Drivers

20. Drivers and their Impact

21. Market Challenges

22. Impact of Drivers and Challenges

23. Market Trends

24. Trends and their Impact

25. Vendor Landscape

  • 25.1. Competitive Scenario
    • 25.1.1. Key News
    • 25.1.2. Mergers and Acquisitions
  • 25.2. Market Share Analysis 2014
    • 25.2.1. Competitive Assessment of Major Drugs
    • 25.2.2. Biogen Idec
    • 25.2.3. Pfizer
    • 25.2.4. Teva Pharmaceutical
    • 25.2.5. Novartis
    • 25.2.6. Merck Serono
    • 25.2.7. UCB
  • 25.3. Other and Potential Future Prominent Vendors

26. Key Vendor Analysis

  • 26.1. Biogen Idec
    • 26.1.1. Key Facts
    • 26.1.2. Business Overview
    • 26.1.3. Business Segmentation by Revenue 2013
    • 26.1.4. Geographical Segmentation by Revenue 2013
    • 26.1.5. Business Strategy
    • 26.1.6. Key Developments
    • 26.1.7. SWOT Analysis
  • 26.2. Merck Serono
    • 26.2.1. Key Facts
    • 26.2.2. Business Overview
    • 26.2.3. Geographical Segmentation by Revenue 2013
    • 26.2.4. Business Strategy
    • 26.2.5. Recent Developments
    • 26.2.6. SWOT Analysis
  • 26.3. Novartis
    • 26.3.1. Key Facts
    • 26.3.2. Business Description
    • 26.3.3. Business Segmentation
    • 26.3.4. Revenue by Business Segmentation
    • 26.3.5. Revenue Comparison 2012 and 2013
    • 26.3.6. Sales by Geography
    • 26.3.7. Business Strategy
    • 26.3.8. Key Developments
    • 26.3.9. SWOT Analysis
  • 26.4. Pfizer
    • 26.4.1. Key Facts
    • 26.4.2. Business Overview
    • 26.4.3. Business Segmentation by Revenue 2013
    • 26.4.4. Business Segmentation by Revenue 2012 and 2013
    • 26.4.5. Geographical Segmentation by Revenue
    • 26.4.6. Business Strategy
    • 26.4.7. Key Developments
    • 26.4.8. SWOT Analysis
  • 26.5. Teva Pharmaceutical
    • 26.5.1. Key Facts
    • 26.5.2. Business Overview
    • 26.5.3. Business Segmentation
    • 26.5.4. Business Segmentation by Revenue 2013
    • 26.5.5. Business Segmentation by Revenue 2012 and 2013
    • 26.5.6. Sales by Geography
    • 26.5.7. Business Strategy
    • 26.5.8. Key Developments
    • 26.5.9. SWOT Analysis
  • 26.6. UCB
    • 26.6.1. Key Facts
    • 26.6.2. Business Overview
    • 26.6.3. Product Segmentation by Revenue 2013
    • 26.6.4. Product Segmentation by Revenue 2012 and 2013
    • 26.6.5. Geographical Segmentation by Revenue 2013
    • 26.6.6. Business Strategy
    • 26.6.7. Recent Developments
    • 26.6.8. SWOT Analysis

27. Other Reports in this Series

List Of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Neurodegenerative Diseases Market 2014-2019 ($ million)
  • Exhibit 3: Segmentation of Global Neurodegenerative Diseases Market by Type of Disease
  • Exhibit 4: Segmentation of Global Neurodegenerative Diseases Market by Type of Disease 2014
  • Exhibit 5: Segmentation of Global Neurodegenerative Diseases Market by Type of Disease 2019
  • Exhibit 6: Etiology of Multiple Sclerosis
  • Exhibit 7: Global Multiple Sclerosis Market 2014-2019 ($ million)
  • Exhibit 8: Multiple Sclerosis Market in US 2014-2019 ($ million)
  • Exhibit 9: Prevalence of Dementia by Geography 2013, 2030, and 2050 (million)
  • Exhibit 10: Prevalence of Dementia by Geography 2013-2018 (millions)
  • Exhibit 11: Types of Dementia and Associated Symptoms
  • Exhibit 12: Types of Dementia by Prevalence 2013
  • Exhibit 13: Segmentation of Economic Burden of Alzheimer's Disease and Other Dementias by Geography 2013
  • Exhibit 14: Average Cost of Care for Americans Aged 65 and Above with Alzheimer's Disease and Other Dementias 2013
  • Exhibit 15: Distribution of Alzheimer's Caregivers by Age 2013
  • Exhibit 16: Projected Prevalence of Dependence 2010 and 2030
  • Exhibit 17: Global Alzheimer's Disease Market 2014-2019 ($ million)
  • Exhibit 18: Global Epilepsy Market 2014-2019 ($ million)
  • Exhibit 19: Epilepsy Market in US 2014-2019 ($ million)
  • Exhibit 20: Epilepsy Market in Europe 2014-2019 ($ million)
  • Exhibit 21: Epilepsy Market in Japan 2014-2019 ($ million)
  • Exhibit 22: Global Parkinson's Disease Market 2014-2019 ($ million)
  • Exhibit 23: Segmentation of Global Parkinson's Disease Market by Country 2014
  • Exhibit 24: Snapshot of Disease
  • Exhibit 25: Prevalence of Huntington's Disease by Geography 2013
  • Exhibit 26: Huntington's Disease: Pipeline Portfolio
  • Exhibit 27: Global Huntington's Disease Market 2014-2019 ($ million)
  • Exhibit 28: Snapshot of Disease
  • Exhibit 29: Amyotrophic Lateral Sclerosis: Pipeline Portfolio
  • Exhibit 30: Global Amyotrophic Lateral Sclerosis Market 2014-2019 ($ million)
  • Exhibit 31: Segmentation of Global Neurodegenerative Diseases Market by Type of Molecule
  • Exhibit 32: Segmentation of Global Neurodegenerative Diseases Market by Type of Molecule 2014
  • Exhibit 33: Segmentation of Global Neurodegenerative Diseases Market by Route of Administration
  • Exhibit 34: Segmentation of Global Neurodegenerative Diseases Market by Route of Administration 2014
  • Exhibit 35: Segmentation of Global Neurodegenerative Diseases Market by Geography 2014
  • Exhibit 36: Global Neurodegenerative Diseases Market Share Analysis 2014
  • Exhibit 37: Major Drugs for Neurodegenerative Diseases by Revenue 2014 ($ million)
  • Exhibit 38: YoY Revenue of Major Drugs for Neurodegenerative Diseases 2011-2014 ($ million)
  • Exhibit 39: Revenue Share of Major Drugs for Neurodegenerative Diseases 2011-2014
  • Exhibit 40: Biogen Idec: Global Revenue of Products 2011-2014 ($ million)
  • Exhibit 41: Biogen Idec: YoY Global Revenue of Avonex 2011-2014 ($ million)
  • Exhibit 42: Biogen Idec: Revenue of Avonex in US 2011-2014 ($ million)
  • Exhibit 43: Biogen Idec: Revenue of Avonex in ROW 2011-2014 ($ million)
  • Exhibit 44: Biogen Idec: YoY Global Revenue of Tysabri 2011-2014 ($ million)
  • Exhibit 45: Biogen Idec: Revenue of Tysabri in US 2011-2014 ($ million)
  • Exhibit 46: Biogen Idec: Revenue of Tysabri in ROW 2011-2014 ($ million)
  • Exhibit 47: Biogen Idec: YoY Global Revenue of Fampyra 2011-2014 ($ million)
  • Exhibit 48: Biogen Idec: Revenue of Plegridy in US and ROW 2014 ($ million)
  • Exhibit 49: Biogen Idec: Revenue of Tecfidera in US and ROW 2013 and 2014 ($ million)
  • Exhibit 50: Pfizer: YoY Global Revenue of Lyrica 2011-2014 ($ million)
  • Exhibit 51: Pfizer: YoY Global Revenue of Neurontin 2011-2013 ($ million)
  • Exhibit 52: Teva Pharmaceutical: YoY Global Revenue of Copaxone 2011-2014 ($ million)
  • Exhibit 53: Teva Pharmaceutical: Quarterly Revenue of Copaxone 2011-2014 ($ million)
  • Exhibit 54: Teva Pharmaceutical: YoY Global Revenue of Azilect 2011-2014 ($ million)
  • Exhibit 55: Teva Pharmaceutical: Quarterly Revenue of Azilect 2011-2014 ($ million)
  • Exhibit 56: Novartis: YoY Global Revenue of Gilenya 2011-2014 ($ million)
  • Exhibit 57: Novartis: Revenue of Gilenya in US and ROW 2011-2013 ($ million)
  • Exhibit 58: Novartis: YoY Global Revenue of Extavia 2011-2014 ($ million)
  • Exhibit 59: Novartis: YoY Global Revenue of Comtan/Stalevo 2011-2014 ($ million)
  • Exhibit 60: Novartis: Revenue of Comtan/Stalevo in US and ROW 2011-2013 ($ million)
  • Exhibit 61: Novartis: YoY Global Revenue of Exelon/Exelon Patch 2011-2014 ($ million)
  • Exhibit 62: Novartis: Revenue of Exelon/Exelon Patch in US and ROW 2011-2013 ($ million)
  • Exhibit 63: Merck Serono: YoY Global Revenue of Rebif 2011-2014 ($ million)
  • Exhibit 64: Merck Serono: Revenue of Rebif in North America 2011-2014 ($ million)
  • Exhibit 65: Merck Serono: Revenue of Rebif in Europe 2011-2014 ($ million)
  • Exhibit 66: Merck Serono: Revenue Share of Rebif by Region 2012-2014
  • Exhibit 67: UCB: YoY Global Revenue of Vimpat 2011-2014 ($ million)
  • Exhibit 68: UCB: YoY Revenue of Vimpat in Europe 2011-2014 ($ million)
  • Exhibit 69: UCB: YoY Revenue of Vimpat in North America 2011-2014 ($ million)
  • Exhibit 70: UCB: YoY Global Revenue of Keppra/Keppra XR 2011-2014 ($ million)
  • Exhibit 71: UCB: YoY Revenue of Keppra/Keppra XR in Europe 2011-2014 ($ million)
  • Exhibit 72: UCB: YoY Revenue of Keppra/Keppra XR in North America 2011-2014 ($ million)
  • Exhibit 73: UCB: YoY Global Revenue of Neupro 2011-2014 ($ million)
  • Exhibit 74: UCB: YoY Revenue of Neupro in Europe 2011-2014 ($ million)
  • Exhibit 75: UCB: YoY Revenue of Neupro in North America 2011-2014 ($ million)
  • Exhibit 76: Biogen Idec: Business Segmentation by Revenue 2013
  • Exhibit 77: Biogen Idec: Geographical Segmentation by Revenue 2013
  • Exhibit 78: Merck Serono: Geographical Segmentation by Revenue 2013
  • Exhibit 79: Novartis AG: Business Segmentation
  • Exhibit 80: Novartis AG: Revenue by Business Segmentation 2013
  • Exhibit 81: Novartis AG: Revenue by Business Segmentation 2012 and 2013 ($ million)
  • Exhibit 82: Novartis AG: Revenue by Geographical Segmentation 2013
  • Exhibit 83: Pfizer: Business Segmentation by Revenue 2013
  • Exhibit 84: Pfizer: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 85: Pfizer: Geographical Segmentation by Revenue 2013
  • Exhibit 86: Teva Pharmaceutical Industries: Business Segmentation
  • Exhibit 87: Teva Pharmaceutical Industries: Business Segmentation by Revenue 2013
  • Exhibit 88: Teva Pharmaceutical Industries: Business Segmentation by Revenue 2012 and 2013 ($ million)
  • Exhibit 89: Teva Pharmaceutical Industries: Sales by Geography 2013
  • Exhibit 90: UCB: Product Segmentation by Revenue 2013
  • Exhibit 91: UCB: Product Segmentation by Revenue 2012 and 2013 ($ million)
  • Exhibit 92: UCB: Geographical Segmentation by Revenue 2013
Back to Top